SE457143B - Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin - Google Patents

Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin

Info

Publication number
SE457143B
SE457143B SE8400851A SE8400851A SE457143B SE 457143 B SE457143 B SE 457143B SE 8400851 A SE8400851 A SE 8400851A SE 8400851 A SE8400851 A SE 8400851A SE 457143 B SE457143 B SE 457143B
Authority
SE
Sweden
Prior art keywords
coenzyme
carnitine
pharmaceutical composition
carnitin
acetyl
Prior art date
Application number
SE8400851A
Other languages
English (en)
Swedish (sv)
Other versions
SE8400851D0 (sv
SE8400851L (sv
Inventor
A Bertelli
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of SE8400851D0 publication Critical patent/SE8400851D0/xx
Publication of SE8400851L publication Critical patent/SE8400851L/xx
Publication of SE457143B publication Critical patent/SE457143B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SE8400851A 1983-02-16 1984-02-16 Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin SE457143B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH858/83A CH655005A5 (it) 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Publications (3)

Publication Number Publication Date
SE8400851D0 SE8400851D0 (sv) 1984-02-16
SE8400851L SE8400851L (sv) 1984-08-17
SE457143B true SE457143B (sv) 1988-12-05

Family

ID=4196830

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8400851A SE457143B (sv) 1983-02-16 1984-02-16 Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin

Country Status (11)

Country Link
US (1) US4599232A (it)
JP (1) JPS59186914A (it)
BE (1) BE898918A (it)
CH (1) CH655005A5 (it)
DE (1) DE3405581A1 (it)
DK (1) DK165167C (it)
FR (1) FR2543827B1 (it)
GB (1) GB2137088B (it)
IT (1) IT1170235B (it)
NL (1) NL192778C (it)
SE (1) SE457143B (it)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209519B (it) * 1984-04-10 1989-08-30 Poli Ind Chimica Spa Composti ad attivita'cardiotrofica.
CH662505A5 (it) * 1985-04-30 1987-10-15 Seuref Ag Composizioni farmaceutiche ad azione protettiva vascolare.
CH670763A5 (it) * 1985-08-02 1989-07-14 Seuref Ag
CH666183A5 (it) * 1985-08-06 1988-07-15 Seuref Ag Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
SE8703321D0 (sv) * 1987-08-27 1987-08-27 Sockerbolaget Ab Kostforsterkning
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
GB8907276D0 (en) * 1989-03-31 1989-05-17 Therapy Advisory Services Limi Health supplement
AT393954B (de) * 1990-02-28 1992-01-10 Bock Orthopaed Ind Verfahren und vorrichtung zur bestimmung von gebrauchseigenschaften eines prothesenschaftes
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
EP0643775B1 (en) * 1992-05-28 2004-07-21 Centre For Molecular Biology And Medicine, Quinone derivatives for enhancing cellular bioenergy
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
DK0969744T3 (da) * 1997-03-27 2003-06-23 Khursheed N Jeejeebhoy Kosttilskud til forbedringer af celleenergetik
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5973004A (en) * 1997-04-04 1999-10-26 Howard; James R. L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
AU7828200A (en) 1999-09-23 2001-04-24 Juvenon Corporation Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
US20070072927A1 (en) * 1999-09-23 2007-03-29 Vita Joseph A Nutritional supplement for increased energy and stamina
WO2001032168A1 (en) 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US20010043983A1 (en) * 2000-01-25 2001-11-22 Hamilton Nathan D. Nutritional supplements for aged pets
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
US6579866B2 (en) 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
KR100685696B1 (ko) * 2001-05-10 2007-02-23 카네카 코포레이션 활성 성분으로 조효소 ｑ를 함유하는 경점막 투여용 조성물
CA2451163A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Agent for preventing or treating organ functional disorders and order dysfunction
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
EP1643863A2 (en) * 2003-07-10 2006-04-12 Carl A. Forest Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
EP1670325A1 (en) 2003-09-29 2006-06-21 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
CN101022793B (zh) * 2004-06-29 2011-05-11 美国益力斯林公司 用以促进新陈代谢和降低活性氧水平的食品组合物
HUE033304T2 (en) 2005-06-01 2017-11-28 Bioelectron Tech Corp Redoxactive therapeutic agents for the treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20050249803A1 (en) * 2005-06-03 2005-11-10 Udell Ronald G Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
EA021818B1 (ru) * 2005-09-15 2015-09-30 Эдисон Фармасьютикалз, Инк. Варианты хвостовой части редокс-активных лекарственных средств для лечения митохондриальных болезней и модуляция биомаркера энергетического обмена q10
WO2007084839A2 (en) * 2006-01-13 2007-07-26 Elixirin Corporation Dietary methods and compositions for enhancing metabolism and reducting reactive oxygen species
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20080020022A1 (en) * 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
JP2009037201A (ja) * 2007-03-14 2009-02-19 Fujifilm Corp 感光性樹脂組成物、それを用いた硬化レリーフパターンの製造方法及び半導体装置
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
ES2306610B1 (es) * 2007-04-16 2009-09-11 Universidad De Sevilla Uso de la l-carnitina para el tratamiento de la hipertension arterial.
JP5343002B2 (ja) * 2007-06-22 2013-11-13 株式会社カネカ 生理活性物質含有組成物
WO2009001787A1 (ja) * 2007-06-22 2008-12-31 Kaneka Corporation 補酵素ｑ１０含有組成物
JP5364580B2 (ja) * 2007-08-22 2013-12-11 株式会社カネカ 還元型補酵素ｑ１０の製造方法、ならびに、その安定化方法
CN101951930A (zh) * 2008-02-19 2011-01-19 阿奈斯特药品株式会社 对身体功能的恢复有用的口服或经肠组合物
EP3827815B1 (en) 2008-09-10 2023-09-06 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
MX391378B (es) 2015-12-17 2025-03-21 Ptc Therapeutics Inc Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene

Also Published As

Publication number Publication date
SE8400851D0 (sv) 1984-02-16
FR2543827A1 (fr) 1984-10-12
CH655005A5 (it) 1986-03-27
DK72284A (da) 1984-08-17
BE898918A (nl) 1984-08-16
DE3405581A1 (de) 1984-10-18
DK72284D0 (da) 1984-02-16
US4599232A (en) 1986-07-08
GB8403668D0 (en) 1984-03-14
GB2137088B (en) 1986-02-05
DK165167C (da) 1993-03-01
JPS59186914A (ja) 1984-10-23
NL192778C (nl) 1998-02-03
JPH027572B2 (it) 1990-02-19
DE3405581C2 (it) 1992-10-22
DK165167B (da) 1992-10-19
FR2543827B1 (fr) 1987-06-12
NL8400488A (nl) 1984-09-17
SE8400851L (sv) 1984-08-17
NL192778B (nl) 1997-10-01
IT8323559A0 (it) 1983-10-31
GB2137088A (en) 1984-10-03
IT1170235B (it) 1987-06-03

Similar Documents

Publication Publication Date Title
SE457143B (sv) Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin
Modanloo et al. Analyzing mitochondrial dysfunction, oxidative stress, and apoptosis: potential role of L-carnitine
US4255449A (en) Method of treating abnormal lipoprote in ratios
Goa et al. l-Carnitine: a preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism
DE69910559T2 (de) Neue fettanaloge zur behandlung der fettleibigkeit
US5977162A (en) Therapeutic treatment for auditory function
Danilenko et al. Metabolic cardioprotection: new conceptsin implementation of cardioprotective effects of meldonium
US6733793B2 (en) Oral composition with insulin-like activities and methods of use
EP0167115B1 (en) New derivatives of l-carnitine
CZ20023935A3 (cs) Preparáty biochemických sloučenin majících roli v bioenergetickém metabolismu buněk a způsob jejich použití
CN112203650A (zh) 使用烟酰胺腺嘌呤二核苷酸(nad+)前体和至少一种酮或酮前体的组合物和方法
US20220288018A1 (en) Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
NL8200022A (nl) Farmaceutische samenstelling, die gamma-butyrobetaine bevat, voor de behandeling van door l-carnitine gebrek teweeggebrachte syndromen.
JPS62120317A (ja) 痴呆症状改善・治療剤
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
DE69315162T2 (de) Verwendung von L-Carnitine und Acyl-L-Carnitinen zur Behandlung von Patienten die an AIDS-verwandten Syndromen leiden und von asymptomatischen HIV-seropositiven Patienten
JPS62190190A (ja) Ｌ−カルニチンのホスホリルアルカノ−ルアミド誘導体類およびその医薬組成物
CH661443A5 (en) Pharmaceutical compositions having metabolic activity
RU2636616C1 (ru) Комбинированное лекарственное средство для первичной нейропротекции
ES2267796T3 (es) Uso de fibratos para la preparacion de un medicamento util en el tratamiento de insuficiencia cardiaca congestiva.
Bessman et al. Ammonia inhibits insulin stimulation of the Krebs cycle: further insight into mechanism of hepatic coma
RU2595815C1 (ru) Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
Kelley et al. Action of 5-thio-D-glucose on D-glucose metabolism: possible mechanism for diabetogenic effect.
WO2015012779A1 (ru) Лекарственное средство кардиопротекторного действия
US20060083779A1 (en) Diiodothyroacetic acid and method of use

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8400851-5

Format of ref document f/p: F

NUG Patent has lapsed